Galapagos NV (GLPGF)
USD 22.39
(0.0%)
USD 22.39
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 51.03 Million EUR | 117.92% |
| 2022 | -194.08 Million EUR | -40.64% |
| 2021 | -138 Million EUR | 16.58% |
| 2020 | -178.63 Million EUR | -142.41% |
| 2019 | 374.24 Million EUR | 1212.3% |
| 2018 | -35.07 Million EUR | 57.7% |
| 2017 | -86.16 Million EUR | -1354.25% |
| 2016 | -8.16 Million EUR | 89.71% |
| 2015 | -118.41 Million EUR | -88.99% |
| 2014 | -30.44 Million EUR | -1499.51% |
| 2013 | -7.82 Million EUR | -121.52% |
| 2012 | 4 Million EUR | 142.64% |
| 2011 | -21.49 Million EUR | -240.49% |
| 2010 | 13.78 Million EUR | 47.71% |
| 2009 | 9.35 Million EUR | 436.41% |
| 2008 | -1.88 Million EUR | 50.5% |
| 2007 | -12.4 Million EUR | 5.06% |
| 2006 | -6.71 Million EUR | -29.96% |
| 2005 | -4.96 Million EUR | -95.01% |
| 2004 | -2.4 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -14.88 Million EUR | -6.61% |
| 2024 Q1 | -7.42 Million EUR | 58.01% |
| 2023 Q3 | -6.24 Million EUR | -188.15% |
| 2023 FY | - EUR | 117.92% |
| 2023 Q1 | 35.32 Million EUR | 131.57% |
| 2023 Q2 | 7.08 Million EUR | -79.96% |
| 2023 Q4 | -45.02 Million EUR | -621.44% |
| 2022 Q2 | -42.47 Million EUR | -148.7% |
| 2022 Q1 | -17.07 Million EUR | -245.75% |
| 2022 FY | - EUR | -40.64% |
| 2022 Q4 | -111.89 Million EUR | -323.27% |
| 2022 Q3 | -26.43 Million EUR | 37.76% |
| 2021 FY | - EUR | 16.58% |
| 2021 Q2 | -31.63 Million EUR | 33.76% |
| 2021 Q4 | 11.71 Million EUR | 116.66% |
| 2021 Q3 | -70.34 Million EUR | -122.38% |
| 2021 Q1 | -47.74 Million EUR | -102.38% |
| 2020 Q2 | -80.8 Million EUR | -306.71% |
| 2020 Q4 | -23.59 Million EUR | 42.68% |
| 2020 FY | - EUR | -142.41% |
| 2020 Q1 | -19.86 Million EUR | 87.11% |
| 2020 Q3 | -41.15 Million EUR | 49.06% |
| 2019 Q2 | -42.94 Million EUR | 14.94% |
| 2019 Q1 | -50.48 Million EUR | -299.15% |
| 2019 FY | - EUR | 1212.3% |
| 2019 Q4 | -154.1 Million EUR | -124.22% |
| 2019 Q3 | 636.16 Million EUR | 1581.38% |
| 2018 Q2 | -31.26 Million EUR | -1.37% |
| 2018 Q4 | 25.35 Million EUR | 89.14% |
| 2018 FY | - EUR | 57.7% |
| 2018 Q3 | 13.4 Million EUR | 142.87% |
| 2018 Q1 | -30.84 Million EUR | 39.46% |
| 2017 Q2 | -20.58 Million EUR | -102.26% |
| 2017 Q1 | -10.17 Million EUR | -110.47% |
| 2017 FY | - EUR | -1354.25% |
| 2017 Q3 | -28.58 Million EUR | -38.88% |
| 2017 Q4 | -50.94 Million EUR | -78.23% |
| 2016 Q2 | -5.91 Million EUR | 91.99% |
| 2016 Q1 | -73.91 Million EUR | -206.2% |
| 2016 Q3 | -23.05 Million EUR | -289.66% |
| 2016 FY | - EUR | 89.71% |
| 2016 Q4 | 97.18 Million EUR | 521.51% |
| 2015 FY | - EUR | -88.99% |
| 2015 Q4 | -24.13 Million EUR | 10.45% |
| 2015 Q3 | -26.95 Million EUR | -40.71% |
| 2015 Q2 | -19.15 Million EUR | -31.01% |
| 2015 Q1 | -14.62 Million EUR | -76.8% |
| 2014 FY | - EUR | -1499.51% |
| 2014 Q4 | -8.27 Million EUR | 13.91% |
| 2014 Q3 | -9.6 Million EUR | -55.57% |
| 2014 Q1 | -6.17 Million EUR | -75.84% |
| 2014 Q2 | -6.17 Million EUR | 0.0% |
| 2013 FY | - EUR | -121.52% |
| 2013 Q1 | -1.02 Million EUR | 0.0% |
| 2013 Q2 | -1.02 Million EUR | 0.0% |
| 2013 Q4 | -3.51 Million EUR | 0.0% |
| 2013 Q3 | -3.51 Million EUR | -241.97% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 FY | - EUR | 142.64% |
| 2011 FY | - EUR | -240.49% |
| 2011 Q2 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 FY | - EUR | 47.71% |
| 2009 Q2 | - EUR | 0.0% |
| 2009 FY | - EUR | 436.41% |
| 2008 FY | - EUR | 50.5% |
| 2007 FY | - EUR | 5.06% |
| 2006 FY | - EUR | -29.96% |
| 2005 FY | - EUR | -95.01% |
| 2004 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.74 Million USD | 3016.402% |
| Skye Bioscience, Inc. | -13.54 Million USD | 476.725% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 45.727% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -9576.49% |
| Qrons Inc. | -40.08 Thousand USD | 127434.647% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 775.661% |
| CSL Limited | 4.78 Billion USD | 98.934% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 393.823% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 1413.924% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 5547.148% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 192.226% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 13998.17% |
| Rebus Holdings, Inc. | -951 Thousand USD | 5466.667% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 8170.29% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 421.6% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 171.847% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 960.816% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 21440.999% |
| SQZ Biotechnologies Company | -64.14 Million USD | 179.57% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 2029.968% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 3422.615% |
| Mesoblast Limited | -62.38 Million USD | 181.804% |
| Marizyme, Inc. | -34.28 Million USD | 248.876% |
| Genus plc | 73.7 Million USD | 30.75% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 871.941% |
| Pharming Group N.V. | 9.87 Million USD | -416.726% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 3531.262% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 1538.879% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 681.817% |
| ContraFect Corporation | -64.99 Million USD | 178.52% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 1227.592% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 3740.798% |
| IMV Inc. | -35.52 Million USD | 243.672% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 2296.254% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 9951.828% |
| ONE Bio Corp. | 13.61 Million USD | -274.912% |
| Accustem Sciences Inc. | -3.74 Million USD | 1462.288% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 205.827% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 4127.757% |
| Q BioMed Inc. | -617.62 Thousand USD | 8363.388% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -1328.807% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 2334.066% |
| Biomind Labs Inc. | -1.03 Million USD | 5033.261% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 228.761% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 1864.566% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 812.68% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -758927.365% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 204248.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 2139.879% |
| GB Sciences, Inc. | -1.41 Million USD | 3694.446% |
| Alpha Cognition Inc. | -9.7 Million USD | 625.851% |
| HST Global, Inc. | -5303.00 USD | 962517.5% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 2581.138% |
| Halberd Corporation | -74.27 Thousand USD | 68809.864% |
| Enzolytics Inc. | -2.12 Million USD | 2505.104% |
| Agentix Corp. | -1.37 Million USD | 3820.56% |
| Resverlogix Corp. | -11.74 Million USD | 534.653% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 1766.234% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -216.02 Million USD | 123.626% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -4093.673% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -476.442% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 3504.95% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -13371.772% |
| AVAX Technologies, Inc. | -6.11 Million USD | 934.942% |
| Zenith Capital Corp. | -8.6 Million USD | 693.04% |
| Genscript Biotech Corporation | -248.71 Million USD | 120.52% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 293062.517% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 2186.156% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 29094.282% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 2756.916% |
| Kadimastem Ltd | -2.62 Million USD | 2044.725% |
| Helix BioMedix, Inc. | -1.04 Million USD | 4977.799% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 28283.535% |
| LadRx Corporation | 412.28 Thousand USD | -12279.118% |
| Cell Source, Inc. | -4.27 Million USD | 1294.539% |
| Regen BioPharma, Inc. | 1.46 Million USD | -3381.482% |
| NovAccess Global Inc. | -1.03 Million USD | 5032.078% |
| Affymax, Inc. | -14.29 Million USD | 457.027% |
| Itoco Inc. | -1.86 Million USD | 2830.719% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 13544.234% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 4673.208% |
| Mobile Lads Corp. | -2.24 Million USD | 2377.259% |
| CytoDyn Inc. | -18.02 Million USD | 383.083% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 64680.091% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 417444.018% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 10608.403% |
| SYBLEU INC | -141.57 Thousand USD | 36150.462% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 4905.699% |
| International Stem Cell Corporation | 202 Thousand USD | -25165.842% |
| Bioxytran, Inc. | -3.82 Million USD | 1435.996% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 97054.787% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 2173.047% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 242.287% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 113515.556% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 1964.025% |
| Neutra Corp. | -181.24 Thousand USD | 28258.811% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 353.172% |
| PureTech Health plc | -11.62 Million USD | 538.952% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 353.19% |
| IXICO plc | -707 Thousand USD | 7318.812% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 764.112% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 205.566% |
| CSL Limited | 4.73 Billion USD | 98.922% |
| Cellectis S.A. | -92.63 Million USD | 155.094% |